Renault J, Giorgi-Renault S, Baron M, Mailliet P, Paoletti C, Cros S, Voisin E
J Med Chem. 1983 Dec;26(12):1715-9. doi: 10.1021/jm00366a011.
With the aim of obtaining new antitumoral agents, a series of 5,8-quinazolinediones was prepared. 5-Amino-6-methoxyquinazoline was oxidized by Fremy's salt to give 6-methoxy-5,8-quinazolinedione. Nucleophilic substitution reaction at C6, electrophilic substitution at C7, and synthesis of 7-amino-6-methoxy-5,8-quinazolinedione, the parent compound of streptonigrin, were studied. These compounds were tested for cytotoxic properties on L1210 leukemia cells in vitro. One of them, 6,7-bis(1-aziridinyl)-5,8-quinazolinedione, which exhibits a high cytotoxic activity (ID50 = 0.08 microM), was further screened in standard antitumor systems, including L1210 leukemia, P388 lymphocytic leukemia, sarcoma 180, and B16 melanocarcinoma. This drug gives a significant antitumoral effect on P388 leukemia but is inactive on other experimental models. Moreover, this compound was found to be highly mutagenic for Salmonella typhimurium TA98 and TA100 strains (Ames test), suggesting that DNA damage could be responsible for its cytotoxicity.
为了获得新的抗肿瘤药物,制备了一系列5,8-喹唑啉二酮。5-氨基-6-甲氧基喹唑啉用弗勒米氏盐氧化得到6-甲氧基-5,8-喹唑啉二酮。研究了6位的亲核取代反应、7位的亲电取代反应以及链黑菌素母体化合物7-氨基-6-甲氧基-5,8-喹唑啉二酮的合成。对这些化合物在体外L1210白血病细胞上的细胞毒性进行了测试。其中一种化合物6,7-双(1-氮丙啶基)-5,8-喹唑啉二酮表现出高细胞毒性活性(ID50 = 0.08 microM),在包括L1210白血病、P388淋巴细胞白血病、肉瘤180和B16黑色素瘤在内的标准抗肿瘤系统中进一步进行了筛选。该药物对P388白血病有显著的抗肿瘤作用,但对其他实验模型无活性。此外,发现该化合物对鼠伤寒沙门氏菌TA98和TA100菌株具有高度致突变性(艾姆斯试验),表明DNA损伤可能是其细胞毒性的原因。